Status and phase
Conditions
Treatments
About
The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with eribulin) is safe and causes few or mild side effects in participants. The researchers will compare this treatment approach to eribulin alone.
Full description
The study includes a safety run-in period in which the first 15 patients enrolled will be assigned to receive the study drug SDX-7320 in combination with eribulin. Upon safety confirmation, randomization will commence for the subsequent 40 patients enrolled.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male or female with histologically and/or cytologically confirmed diagnosis of triple-negative metastatic breast cancer defined as estrogen and progesterone receptor staining <10%; and HER2-negative defined as IHC 0 to 1+ (note: if IHC is equivocal, non-amplified status by FISH is acceptable)
Advanced (local regionally recurrent, not amenable to curative therapy or surgery) or metastatic stage with up to 2 prior lines of therapy in the advanced or metastatic setting
Received prior anthracycline and taxane chemotherapy in the neoadjuvant, adjuvant, or metastatic settings and considered appropriate for treatment with single agent eribulin
Evidence of metabolic dysfunction defined as HbA1c > 5.5 and/or BMI ≥ 30 kg/m^2
Measurable disease per the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), OR at least one evaluable, predominantly lytic bone lesion
Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≤1.
Adult ≥18 at the time of informed consent and has provided written informed consent before the performance of any study-related activities and according to local guidelines.
Adequate bone marrow and organ function as defined by the following laboratory values (as assessed by central laboratory for eligibility):
Patient is, in the Investigator's opinion, willing and able to comply with the study requirements, including the ability to fast prior to treatment days.
If sexually active female of childbearing potential, willing to use a contraception method listed below:
If a sexually active male, willing to use barrier contraception (condoms)
Exclusion criteria
Three or greater prior lines of therapy for metastatic TNBC
Known primary brain malignancy, brain metastases or active CNS pathology, any of which as determined by the Investigator
Currently participating in a study of an investigational agent
Body mass index < 18.5 kg/m2
Known hypersensitivity to SDX-7320 or eribulin
Established diagnosis of diabetes mellitus type I or uncontrolled or insulin-dependent type II. Uncontrolled is defined as fasting blood glucose >140 mg/dL and/or HbA1c ≥8%
Use of combination antihyperglycemic therapy (single agent metformin on stable dose for at least 3 months prior to enrollment is allowable)
Child Pugh score of B or C.
Concurrent malignancy or malignancy within 3 years of randomization, with the exception of adequately treated, basal or squamous cell carcinoma, nonmelanomatous skin cancer or curatively resected cervical cancer.
Uncontrolled human immunodeficiency virus (HIV) infection. (Testing is not mandatory.)
Evidence of uncontrolled active Hepatitis B or C infection
History of Stevens-Johnson Syndrome (SJS), erythema multiforme (EM), toxic epidermal necrolysis (TEN), or other severe medication-related cutaneous reactions.
Any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, contraindicate patient participation in the clinical study (e.g., chronic active hepatitis, severe hepatic impairment).
Clinically significant, uncontrolled heart disease and/or recent cardiac events including any of the following:
Currently receiving any of the following medications and cannot be discontinued 7 days prior to the start of the treatment: Medications with a known risk to prolong the QT interval or induce Torsade de Pointes (TdP). CredibleMeds list of drugs known to cause TdP may be used as a reference for this study to determine which drugs are prohibited using the following link: https://crediblemeds.org/new-drug-list or a crediblemeds mobile application.
°Herbal preparations/medications, with the exception of cannabinoids, CBD compounds, etc.
Participation in a prior investigational study within 14 days prior to the start of the study treatment or within 5 half-lives of study drug, whichever is longer.
History of acute pancreatitis within 1 year of Screening or past medical history of chronic pancreatitis
Pregnant patients
Primary purpose
Allocation
Interventional model
Masking
55 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Tiffany Trainia, MD; Neil Iyengar, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal